$2,600 per signed retainer on a tort where the plaintiff demographic is one of the most precisely targetable populations in advertising. That’s the gap.
Hair relaxer isn’t like other mass torts. The plaintiff pool maps almost perfectly to a single demographic: Black women who used chemical straightening products for years. That changes the entire advertising playbook.
11,440 cases in the MDL. Growing 17% year-over-year. And the most important date in the litigation is 26 days away.
The MDL
MDL 3060 sits in the Northern District of Illinois under Judge Mary M. Rowland. Created February 2023. Over 15,319 total cases filed, with 11,440+ currently pending.
January 8, 2026: Science Day. Both sides presented their scientific evidence to the judge. The pre-Daubert overview that shapes everything that follows.
April 1, 2026: the Daubert deadline. Defendants challenge plaintiffs’ expert testimony on causation. This is the single most important date in hair relaxer litigation.
If the experts survive, settlement pressure accelerates and case values go up. If they don’t, the MDL stalls.
A Settlement Master was appointed in May 2025. No global settlement talks announced. Everyone’s waiting on Daubert.
The Science
The NIH Sister Study in October 2022 broke this litigation open. Thirty-three thousand women followed for 11 years.
The finding: women who used hair straightening products four or more times per year were 2.55 times more likely to develop uterine cancer. Lifetime risk jumped from 1.64% to 4.05%.
Sixty percent of participants who used straighteners were Black women.
The supporting research is deep. The Black Women’s Health Study found over 50% increased uterine cancer risk for postmenopausal women using relaxers twice or more per year. Another NIH study linked frequent use to 2.19 times higher ovarian cancer risk. CDC biomarker data showed Black women who used hair products had 16% higher phthalate levels and 35% higher paraben concentrations.
Formaldehyde is classified as a Group 1 carcinogen by IARC. It’s in these products. The FDA proposed banning it in hair straighteners in October 2023 but missed its own April 2024 deadline. California banned it effective January 2025.
The science is strong. Whether it survives Daubert challenges on April 1 determines this tort’s future.
The Lead Economics
Lead costs dropped hard from the 2023 gold rush.
At peak (February 2023): $1,000 per lead, $1,667 per signed retainer. $1.4 million per month in TV alone.
Now: $225-$430 per raw lead. $1,800-$2,600 per signed retainer. The initial surge is over. The smart money is still acquiring.
Projected settlement values: $150,000-$750,000 per cancer claim. Conservative estimates start at $120,000-$150,000. Strong cases with documented diagnoses and long usage histories could reach $300,000 or higher.
The MOIC math on a $2,600 signed retainer against a $300,000 settlement is 115:1. Even at the conservative floor ($120,000), that’s 46:1.
Qualification rates sit around 15-20% from lead to signed case. Tighter than most mass torts because the criteria are specific: documented cancer diagnosis, minimum four years of product use, specific brand requirements, and age restrictions.
Who’s Being Sued
L’Oreal is the primary target. Dark & Lovely, Optimum, Mizani, SoftSheen-Carson. They’re fighting everything. Lost an appeal to dismiss in Georgia. Plaintiffs are pushing for parent company documents.
Revlon is in bankruptcy. Set aside $44 million for claims. Limited ammunition.
Namaste Laboratories (ORS Olive Oil) lost a motion to dismiss in December 2025. A court compelled them to release withheld internal emails about product formulation and safety testing. That discovery is the kind of evidence that moves settlement math.
Strength of Nature (African Pride, TCB, Motions, Just for Me), Dabur International, John Paul Mitchell Systems, Wella, PDC Brands (Cantu), McBride Research (Design Essentials). All fighting. All in the MDL.
No global settlement. The April 1 Daubert deadline determines who starts talking.
The Advertising Playbook Is Different
This is where hair relaxer breaks from every other mass tort.
Broadcast doesn’t work. The plaintiff demographic is Black women 25-64 who used chemical straighteners for years. That’s not the daytime TV audience buying Camp Lejeune or mesothelioma ads. TV spend hit $1.4 million per month in February 2023 and has largely dried up since.
Social media is the primary channel. About 50% of current spend. Meta platforms allow precise demographic and interest targeting. Hair care communities, beauty interest segments, natural hair audiences. The targeting is accurate because the demographic is specific.
CTV is the underused opportunity at 15%. Black households over-index on ad-supported streaming: Tubi, Peacock, BET+, YouTube. Household-level targeting and attribution that broadcast can’t match. This is a tort where behavioral and demographic CTV targeting meaningfully concentrates spend versus broadcast.
Search captures 25%. “Hair relaxer lawsuit” and “hair relaxer cancer” keywords are competitive but the intent is strong.
The firms still running broadcast for hair relaxer are wasting money. The demographic dictates the channel. Period.
The Demographic Reality
Eighty-four to 95% of Black women in the US have used relaxers. Many started in childhood. The products were intentionally marketed to Black women and girls as tools for professional and social acceptance.
That marketing history is now both a legal argument and an advertising advantage. Targeted negligence: the companies knew who was buying and kept selling. Targeted advertising: firms know exactly who to reach.
But the specificity cuts both ways. Community trust matters more here than any other mass tort. Heavy-handed “you may be entitled to compensation” broadcast spots don’t land with this audience. A trusted Instagram creator discussing her cancer journey drives more signed retainers than $100,000 in TV.
Church and community organization partnerships. Natural hair influencers. Beauty-focused social accounts. These aren’t traditional mass tort advertising channels. They’re the channels that work for this tort.
Qualification Criteria
The screening bar is specific. Person of Color of African American descent with naturally textured or curly hair.
Cancer diagnosis required: uterine, ovarian (serous, endometrioid, mucinous, clear cell), or endometrial. Diagnosed in 2010 or later.
Product use: minimum four continuous years before diagnosis. At least four applications per year during peak use period. Diagnosis must occur within 10 years of last use.
Age at diagnosis: 59 or younger.
Brand requirement: must identify the product by name. Must contain formaldehyde or phthalates. Acceptable brands include Dark & Lovely, Africa’s Best, TCB Naturals, Just For Me, Mizani, Motions, Optimum, Soft & Beautiful, African Pride.
Revlon-only use is excluded. Michigan and Texas residents are disqualified for some firms.
Not represented. Not incarcerated. Valid SSN.
The Play
Hair relaxer is in the buy-low window. Three things matter right now.
First, April 1 is the date. The Daubert ruling determines whether this tort accelerates or stalls. Firms acquiring cases now at $1,800-$2,600 are betting the science survives. If it does, those CPAs double by Q4.
Second, kill the broadcast budget. This tort is social-first, community-driven, CTV-supported. Meta for lead capture. CTV on platforms like BET+ and Tubi for top-of-funnel awareness. Paid search for intent. Broadcast is a demographic mismatch.
Third, the messaging matters more here. This isn’t a tort where you blast volume and sort later. The plaintiff community has a specific history with being marketed harmful products. Cultural sensitivity isn’t a nice-to-have. It’s a conversion requirement.
The firms winning hair relaxer cases aren’t the biggest spenders. They’re the ones running through community channels, qualifying on documentation, and waiting for April 1 with full portfolios.
References
- In Re: Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation, MDL No. 3060, N.D. Illinois
- Chang C, et al. Use of Straighteners and Other Hair Products and Incident Uterine Cancer. Journal of the National Cancer Institute. 2022;114(12):1636-1645
- Whitehardt Mass Tort Report: Hot Tort Rankings and Lead Economics, Q1 2026
- CDC National Biomonitoring Program. Chemical Exposures in Hair Products, 2024
- FDA Proposed Rule: Banning Formaldehyde in Hair Straightening Products, October 2023